Orange Book product · Brand (NDA)
LIORESAL
BACLOFEN
At a glance
Jun 17, 1992
Approved
Brand (NDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jun 17, 1992
34 yr 6 mo ago
Today
Pharmaceutical detail
Active ingredient
BACLOFEN
Strength
2MG/ML
Dosage form
INJECTABLE
Route
INTRATHECAL
TE code
AP
Application
NDA 020075
Product number
002
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2022FLEQSUVYBrand (NDA)
NDA 215602 · AZURITY
- 2021LYVISPAHBrand (NDA)
NDA 215422 · STRIDES PHARMA INTL
- 2019OZOBAXBrand (NDA)
NDA 208193 · METACEL PHARMS LLC
- 2010GABLOFENBrand (NDA)
NDA 022462 · PIRAMAL CRITICAL
- 2003KEMSTROBrand (NDA)
NDA 021589 · UCB INC
- —LIORESALBrand (NDA)
NDA 017851 · NOVARTIS
- 2025BACLOFENGeneric (ANDA)
ANDA 214099 · AUROBINDO PHARMA LTD
- 2025BACLOFENGeneric (ANDA)
ANDA 090334 · SOMERSET THERAPS LLC
- 2024BACLOFENGeneric (ANDA)
ANDA 214445 · RUBICON RESEARCH
- 2024BACLOFENGeneric (ANDA)
ANDA 217788 · RISING
- 2023BACLOFENGeneric (ANDA)
ANDA 217687 · MICRO LABS
- 2023BACLOFENGeneric (ANDA)
ANDA 214114 · REGCON HOLDINGS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
